A new safeguard eliminates T cell receptor gene-modified auto-reactive T cells after adoptive therapyElisa KiebackTo my parents11.112604#27431.241.2.151.2.261.31.3.171.3.21.3.381.3.491.41.4.110603#2441.4.211603#3131.4.3121.4.4131.514152152.12.1.116172.1.22.1.3182.1.42.1.52.1.6192.22.2.1380#37220212223242526272.2.22829303132333435362.33738394041424344454647484950513513.1369#3665253623#25254642#4473.2484#60455502#55356378#30857506#470583.3642#260593.4642#274603.5624#18461598#18862642#2983.663443#2913.764566#5026566575#281498#24567522#32268574#2923.8642#19569642#1883.970566#2474714.1724.2734.3744.4754.5764.6774.6.14.6.2784.74.7.14.7.2794.7.3804.7.44.7.5814.882 Abbreviations ReferencesAcknowledgements PublicationsStatementdeInhaltsverzeichnisHilfe References [1] Carding, S. R. and Egan, P. J. (2002): Gammadelta T cells: functional plasticity and heterogeneity, Nat Rev Immunol 2 [5], pp.336-45. [2] Kabelitz, D.; Wesch, D. and He, W. (2007): Perspectives of gammadelta T cells in tumor immunology, Cancer Res 67 [1], pp.5-8. [3] Rudolph, M. G.; Stanfield, R. L. and Wilson, I. A. (2006): How TCRs bind MHCs, peptides, and coreceptors, Annu Rev Immunol 24, pp.419-66. [4] Rudolph, M. G.; Luz, J. G. and Wilson, I. A. (2002): Structural and thermodynamic correlates of T cell signaling, Annu Rev Biophys Biomol Struct 31, pp.121-49. [5] Marrack, P.; Scott-Browne, J. P.; Dai, S.; Gapin, L. and Kappler, J. W. (2008): Evolutionarily conserved amino acids that control TCR-MHC interaction, Annu Rev Immunol 26, pp.171-203. [6] Garcia, K. C.; Degano, M.; Stanfield, R. L.; Brunmark, A.; Jackson, M. R.; Peterson, P. A.; Teyton, L. and Wilson, I. A. (1996): An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex, Science 274 [5285], pp.209-19. [7] Leisegang, M.; Engels, B.; Meyerhuber, P.; Kieback, E.; Sommermeyer, D.; Xue, S. A.; Reuss, S.; Stauss, H. and Uckert, W. (2008): Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette, J Mol Med. [8] Kearse, K. P.; Roberts, J. L.; Munitz, T. I.; Wiest, D. L.; Nakayama, T. and Singer, A. (1994): Developmental regulation of alpha beta T cell antigen receptor expression results from differential stability of nascent TCR alpha proteins within the endoplasmic reticulum of immature and mature T cells, Embo J 13 [19], pp.4504-14. [9] Manolios, N.; Letourneur, F.; Bonifacino, J. S. and Klausner, R. D. (1991): Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor, Embo J 10 [7], pp.1643-51. [10] Sun, Z. J.; Kim, K. S.; Wagner, G. and Reinherz, E. L. (2001): Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain fragment of the CD3 epsilon gamma heterodimer, Cell 105 [7], pp.913-23. [11] Alarcon, B.; Swamy, M.; van Santen, H. M. and Schamel, W. W. (2006): T-cell antigen-receptor stoichiometry: pre-clustering for sensitivity, EMBO Rep 7 [5], pp.490-5. [12] Call, M. E.; Pyrdol, J. and Wucherpfennig, K. W. (2004): Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum, Embo J 23 [12], pp.2348-57. [13] Boniface, J. J.; Rabinowitz, J. D.; Wulfing, C.; Hampl, J.; Reich, Z.; Altman, J. D.; Kantor, R. M.; Beeson, C.; McConnell, H. M. and Davis, M. M. (1998): Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected], Immunity 9 [4], pp.459-66. [14] Minguet, S.; Swamy, M.; Alarcon, B.; Luescher, I. F. and Schamel, W. W. (2007): Full activation of the T cell receptor requires both clustering and conformational changes at CD3, Immunity 26 [1], pp.43-54. [15] Stone, J. D. and Stern, L. J. (2006): CD8 T cells, like CD4 T cells, are triggered by multivalent engagement of TCRs by MHC-peptide ligands but not by monovalent engagement, J Immunol 176 [3], pp.1498-505. [16] Ghendler, Y.; Smolyar, A.; Chang, H. C. and Reinherz, E. L. (1998): One of the CD3epsilon subunits within a T cell receptor complex lies in close proximity to the Cbeta FG loop, J Exp Med 187 [9], pp.1529-36. [17] Geisler, C.; Rubin, B.; Caspar-Bauguil, S.; Champagne, E.; Vangsted, A.; Hou, X. and Gajhede, M. (1992): Structural mutations of C-domains in members of the Ig superfamily. Consequences for the interactions between the T cell antigen receptor and the zeta 2 homodimer, J Immunol 148 [11], pp.3469-77. [18] Ehrlich, P. (1909): Ueber den jetzigen Stand der Karzinomforschung, Ned. Tijdschr. Geneeskd. 5 [(Part 1)], pp.273-90. [19] Thomas, L. (1959): Discussion, Lawrence, H.S., Ed, Cellular and Humoral Aspects of the Hypersensitivitive States, Hoeber-Harper,

New York

. [20] Burnet, FM. (1970): The concept of immunological surveillance, Prog. Exp. Tumor Res. [12], pp.1-27. [21] Qin, Z. and Blankenstein, T. (2004): A cancer immunosurveillance controversy, Nat Immunol 5 [1], pp.3-4; author reply 4-5. [22] Dunn, G. P.; Old, L. J. and Schreiber, R. D. (2004): The three Es of cancer immunoediting, Annu Rev Immunol 22, pp.329-60. [23] Novellino, L.; Castelli, C. and Parmiani, G. (2005): A listing of human tumor antigens recognized by T cells: March 2004 update, Cancer Immunol Immunother 54 [3], pp.187-207. [24] Willimsky, G. and Blankenstein, T. (2005): Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance, Nature 437 [7055], pp.141-6. [25] Zhang, B.; Bowerman, N. A.; Salama, J. K.; Schmidt, H.; Spiotto, M. T.; Schietinger, A.; Yu, P.; Fu, Y. X.; Weichselbaum, R. R.; Rowley, D. A.; Kranz, D. M. and Schreiber, H. (2007): Induced sensitization of tumor stroma leads to eradication of established cancer by T cells, J Exp Med 204 [1], pp.49-55. [26] Kolb, H. J.; Schattenberg, A.; Goldman, J. M.; Hertenstein, B.; Jacobsen, N.; Arcese, W.; Ljungman, P.; Ferrant, A.; Verdonck, L.; Niederwieser, D.; van Rhee, F.; Mittermueller, J.; de Witte, T.; Holler, E. and Ansari, H. (1995): Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients, Blood 86 [5], pp.2041-50. [27] Falkenburg, J. H.; Wafelman, A. R.; Joosten, P.; Smit, W. M.; van Bergen, C. A.; Bongaerts, R.; Lurvink, E.; van der Hoorn, M.; Kluck, P.; Landegent, J. E.; Kluin-Nelemans, H. C.; Fibbe, W. E. and Willemze, R. (1999): Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes, Blood 94 [4], pp.1201-8. [28] Bleakley, M. and Riddell, S. R. (2004): Molecules and mechanisms of the graft-versus-leukaemia effect, Nat Rev Cancer 4 [5], pp.371-80. [29] Goulmy, E. (2004): Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy, Cancer J 10 [1], pp.1-7. [30] Horowitz, M. M.; Gale, R. P.; Sondel, P. M.; Goldman, J. M.; Kersey, J.; Kolb, H. J.; Rimm, A. A.; Ringden, O.; Rozman, C.; Speck, B. and et al. (1990): Graft-versus-leukemia reactions after bone marrow transplantation, Blood 75 [3], pp.555-62. [31] Rooney, C. M.; Smith, C. A.; Ng, C. Y.; Loftin, S. K.; Sixbey, J. W.; Gan, Y.; Srivastava, D. K.; Bowman, L. C.; Krance, R. A.; Brenner, M. K. and Heslop, H. E. (1998): Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients, Blood 92 [5], pp.1549-55. [32] Roskrow, M. A.; Suzuki, N.; Gan, Y.; Sixbey, J. W.; Ng, C. Y.; Kimbrough, S.; Hudson, M.; Brenner, M. K.; Heslop, H. E. and Rooney, C. M. (1998): Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease, Blood 91 [8], pp.2925-34. [33] Haque, T.; Wilkie, G. M.; Taylor, C.; Amlot, P. L.; Murad, P.; Iley, A.; Dombagoda, D.; Britton, K. M.; Swerdlow, A. J. and Crawford, D. H. (2002): Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells, Lancet 360 [9331], pp.436-42. [34] Comoli, P.; Labirio, M.; Basso, S.; Baldanti, F.; Grossi, P.; Furione, M.; Vigano, M.; Fiocchi, R.; Rossi, G.; Ginevri, F.; Gridelli, B.; Moretta, A.; Montagna, D.; Locatelli, F.; Gerna, G. and Maccario, R. (2002): Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication, Blood 99 [7], pp.2592-8. [35] Walter, E. A.; Greenberg, P. D.; Gilbert, M. J.; Finch, R. J.; Watanabe, K. S.; Thomas, E. D. and Riddell, S. R. (1995): Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor, N Engl J Med 333 [16], pp.1038-44. [36] Reusser, P.; Attenhofer, R.; Hebart, H.; Helg, C.; Chapuis, B. and Einsele, H. (1997): Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants, Blood 89 [10], pp.3873-9. [37] Peggs, K. S.; Verfuerth, S.; Pizzey, A.; Khan, N.; Guiver, M.; Moss, P. A. and Mackinnon, S. (2003): Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines, Lancet 362 [9393], pp.1375-7. [38] Dudley, M. E. and Rosenberg, S. A. (2003): Adoptive-cell-transfer therapy for the treatment of patients with cancer, Nat Rev Cancer 3 [9], pp.666-75. [39] Yannelli, J. R.; Hyatt, C.; McConnell, S.; Hines, K.; Jacknin, L.; Parker, L.; Sanders, M. and Rosenberg, S. A. (1996): Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience, Int J Cancer 65 [4], pp.413-21. [40] Yee, C.; Thompson, J. A.; Byrd, D.; Riddell, S. R.; Roche, P.; Celis, E. and Greenberg, P. D. (2002): Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc Natl Acad Sci U S A 99 [25], pp.16168-73. [41] Dudley, M. E.; Wunderlich, J. R.; Robbins, P. F.; Yang, J. C.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Sherry, R.; Restifo, N. P.; Hubicki, A. M.; Robinson, M. R.; Raffeld, M.; Duray, P.; Seipp, C. A.; Rogers-Freezer, L.; Morton, K. E.; Mavroukakis, S. A.; White, D. E. and Rosenberg, S. A. (2002): Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science 298 [5594], pp.850-4. [42] Eshhar, Z.; Waks, T.; Gross, G. and Schindler, D. G. (1993): Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors, Proc Natl Acad Sci U S A 90 [2], pp.720-4. [43] Eshhar, Z. (1997): Tumor-specific T-bodies: towards clinical application, Cancer Immunol Immunother 45 [3-4], pp.131-6. [44] Lamers, C. H.; Langeveld, S. C.; Groot-van Ruijven, C. M.; Debets, R.; Sleijfer, S. and Gratama, J. W. (2007): Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo, Cancer Immunol Immunother 56 [12], pp.1875-83. [45] Xue, S. A.; Gao, L.; Hart, D.; Gillmore, R.; Qasim, W.; Thrasher, A.; Apperley, J.; Engels, B.; Uckert, W.; Morris, E. and Stauss, H. (2005): Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells, Blood 106 [9], pp.3062-7. [46] Stanislawski, T.; Voss, R. H.; Lotz, C.; Sadovnikova, E.; Willemsen, R. A.; Kuball, J.; Ruppert, T.; Bolhuis, R. L.; Melief, C. J.; Huber, C.; Stauss, H. J. and Theobald, M. (2001): Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer, Nat Immunol 2 [10], pp.962-70. [47] Kuball, J.; Schuler, M.; Antunes Ferreira, E.; Herr, W.; Neumann, M.; Obenauer-Kutner, L.; Westreich, L.; Huber, C.; Wolfel, T. and Theobald, M. (2002): Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man, Gene Ther 9 [13], pp.833-43. [48] Li, Y.; Moysey, R.; Molloy, P. E.; Vuidepot, A. L.; Mahon, T.; Baston, E.; Dunn, S.; Liddy, N.; Jacob, J.; Jakobsen, B. K. and Boulter, J. M. (2005): Directed evolution of human T-cell receptors with picomolar affinities by phage display, Nat Biotechnol 23 [3], pp.349-54. [49] Holler, P. D.; Holman, P. O.; Shusta, E. V.; O'Herrin, S.; Wittrup, K. D. and Kranz, D. M. (2000): In vitro evolution of a T cell receptor with high affinity for peptide/MHC, Proc Natl Acad Sci U S A 97 [10], pp.5387-92. [50] Chlewicki, L. K.; Holler, P. D.; Monti, B. C.; Clutter, M. R. and Kranz, D. M. (2005): High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3, J Mol Biol 346 [1], pp.223-39. [51] Schumacher, T. N. (2002): T-cell-receptor gene therapy, Nat Rev Immunol 2 [7], pp.512-9. [52] Engels, B. and Uckert, W. (2007): Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy, Mol Aspects Med 28 [1], pp.115-42. [53] Stauss, H. J.; Cesco-Gaspere, M.; Thomas, S.; Hart, D. P.; Xue, S. A.; Holler, A.; Wright, G.; Perro, M.; Little, A. M.; Pospori, C.; King, J. and Morris, E. C. (2007): Monoclonal T-cell receptors: new reagents for cancer therapy, Mol Ther 15 [10], pp.1744-50. [54] Rosenberg, S. A.; Restifo, N. P.; Yang, J. C.; Morgan, R. A. and Dudley, M. E. (2008): Adoptive cell transfer: a clinical path to effective cancer immunotherapy, Nat Rev Cancer 8 [4], pp.299-308. [55] Morgan, R. A.; Dudley, M. E.; Wunderlich, J. R.; Hughes, M. S.; Yang, J. C.; Sherry, R. M.; Royal, R. E.; Topalian, S. L.; Kammula, U. S.; Restifo, N. P.; Zheng, Z.; Nahvi, A.; de Vries, C. R.; Rogers-Freezer, L. J.; Mavroukakis, S. A. and Rosenberg, S. A. (2006): Cancer regression in patients after transfer of genetically engineered lymphocytes, Science 314 [5796], pp.126-9. [56] Engels, B.; Cam, H.; Schuler, T.; Indraccolo, S.; Gladow, M.; Baum, C.; Blankenstein, T. and Uckert, W. (2003): Retroviral vectors for high-level transgene expression in T lymphocytes, Hum Gene Ther 14 [12], pp.1155-68. [57] Kammertoens, T.; Schuler, T. and Blankenstein, T. (2005): Immunotherapy: target the stroma to hit the tumor, Trends Mol Med 11 [5], pp.225-31. [58] Blankenstein, T. (2005): The role of tumor stroma in the interaction between tumor and immune system, Curr Opin Immunol 17 [2], pp.180-6. [59] Overwijk, W. W.; Theoret, M. R.; Finkelstein, S. E.; Surman, D. R.; de Jong, L. A.; Vyth-Dreese, F. A.; Dellemijn, T. A.; Antony, P. A.; Spiess, P. J.; Palmer, D. C.; Heimann, D. M.; Klebanoff, C. A.; Yu, Z.; Hwang, L. N.; Feigenbaum, L.; Kruisbeek, A. M.; Rosenberg, S. A. and Restifo, N. P. (2003): Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells, J Exp Med 198 [4], pp.569-80. [60] Weinhold, M.; Sommermeyer, D.; Uckert, W. and Blankenstein, T. (2007): Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity, J Immunol 179 [8], pp.5534-42. [61] Sommermeyer, D.; Neudorfer, J.; Weinhold, M.; Leisegang, M.; Engels, B.; Noessner, E.; Heemskerk, M. H.; Charo, J.; Schendel, D. J.; Blankenstein, T.; Bernhard, H. and Uckert, W. (2006): Designer T cells by T cell receptor replacement, Eur J Immunol 36 [11], pp.3052-9. [62] Heemskerk, M. H.; Hagedoorn, R. S.; van der Hoorn, M. A.; van der Veken, L. T.; Hoogeboom, M.; Kester, M. G.; Willemze, R. and Falkenburg, J. H. (2007): Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex, Blood 109 [1], pp.235-43. [63] Kuball, J.; Dossett, M. L.; Wolfl, M.; Ho, W. Y.; Voss, R. H.; Fowler, C. and Greenberg, P. D. (2007): Facilitating matched pairing and expression of TCR chains introduced into human T cells, Blood 109 [6], pp.2331-8. [64] Cohen, C. J.; Li, Y. F.; El-Gamil, M.; Robbins, P. F.; Rosenberg, S. A. and Morgan, R. A. (2007): Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond, Cancer Res 67 [8], pp.3898-903. [65] Chang, H. C.; Bao, Z.; Yao, Y.; Tse, A. G.; Goyarts, E. C.; Madsen, M.; Kawasaki, E.; Brauer, P. P.; Sacchettini, J. C.; Nathenson, S. G. and et al. (1994): A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments, Proc Natl Acad Sci U S A 91 [24], pp.11408-12. [66] Voss, R. H.; Willemsen, R. A.; Kuball, J.; Grabowski, M.; Engel, R.; Intan, R. S.; Guillaume, P.; Romero, P.; Huber, C. and Theobald, M. (2008): Molecular design of the Calpha interface favors specific pairing of introduced TCRalpha in human T cells, J Immunol 180 [1], pp.391-401. [67] Voss, R. H.; Kuball, J.; Engel, R.; Guillaume, P.; Romero, P.; Huber, C. and Theobald, M. (2006): Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression, Immunol Res 34 [1], pp.67-87. [68] Cohen, C. J.; Zhao, Y.; Zheng, Z.; Rosenberg, S. A. and Morgan, R. A. (2006): Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability, Cancer Res 66 [17], pp.8878-86. [69] Willemsen, R. A.; Weijtens, M. E.; Ronteltap, C.; Eshhar, Z.; Gratama, J. W.; Chames, P. and Bolhuis, R. L. (2000): Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR, Gene Ther 7 [16], pp.1369-77. [70] van der Veken, L. T.; Hagedoorn, R. S.; van Loenen, M. M.; Willemze, R.; Falkenburg, J. H. and Heemskerk, M. H. (2006): Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity, Cancer Res 66 [6], pp.3331-7. [71] Hah, C.; Kim, M. and Kim, K. (2005): Induction of peripheral tolerance in dual TCR T cells: an evidence for non-dominant signaling by one TCR, J Biochem Mol Biol 38 [3], pp.334-42. [72] Gladow, M.; Uckert, W. and Blankenstein, T. (2004): Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors, Eur J Immunol 34 [7], pp.1882-91. [73] Hafler, D. A. and Weiner, H. L. (1995): Immunologic mechanisms and therapy in multiple sclerosis, Immunol Rev 144, pp.75-107. [74] Bach, J. F. and Chatenoud, L. (2001): Tolerance to islet autoantigens in type 1 diabetes, Annu Rev Immunol 19, pp.131-61. [75] Heemskerk, M. H.; Hoogeboom, M.; Hagedoorn, R.; Kester, M. G.; Willemze, R. and Falkenburg, J. H. (2004): Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer, J Exp Med 199 [7], pp.885-94. [76] Kershaw, M. H.; Westwood, J. A. and Hwu, P. (2002): Dual-specific T cells combine proliferation and antitumor activity, Nat Biotechnol 20 [12], pp.1221-7. [77] Cooper, L. J.; Al-Kadhimi, Z.; Serrano, L. M.; Pfeiffer, T.; Olivares, S.; Castro, A.; Chang, W. C.; Gonzalez, S.; Smith, D.; Forman, S. J. and Jensen, M. C. (2005): Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1, Blood 105 [4], pp.1622-31. [78] Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffraat, N.; McIntyre, E.; Radford, I.; Villeval, J. L.; Fraser, C. C.; Cavazzana-Calvo, M. and Fischer, A. (2003): A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency, N Engl J Med 348 [3], pp.255-6. [79] Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M.; McCormack, M. P.; Wulffraat, N.; Leboulch, P.; Lim, A.; Osborne, C. S.; Pawliuk, R.; Morillon, E.; Sorensen, R.; Forster, A.; Fraser, P.; Cohen, J. I.; de Saint Basile, G.; Alexander, I.; Wintergerst, U.; Frebourg, T.; Aurias, A.; Stoppa-Lyonnet, D.; Romana, S.; Radford-Weiss, I.; Gross, F.; Valensi, F.; Delabesse, E.; Macintyre, E.; Sigaux, F.; Soulier, J.; Leiva, L. E.; Wissler, M.; Prinz, C.; Rabbitts, T. H.; Le Deist, F.; Fischer, A. and Cavazzana-Calvo, M. (2003): LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science 302 [5644], pp.415-9. [80] Baum, C. (2007): Fourth case of leukemia in the first SCID-XI gene therapy trial and the diversity of gene therapy, Commentary from the Board of the European society of Gene and Cell Therapy. [81] Deichmann, A.; Hacein-Bey-Abina, S.; Schmidt, M.; Garrigue, A.; Brugman, M. H.; Hu, J.; Glimm, H.; Gyapay, G.; Prum, B.; Fraser, C. C.; Fischer, N.; Schwarzwaelder, K.; Siegler, M. L.; de Ridder, D.; Pike-Overzet, K.; Howe, S. J.; Thrasher, A. J.; Wagemaker, G.; Abel, U.; Staal, F. J.; Delabesse, E.; Villeval, J. L.; Aronow, B.; Hue, C.; Prinz, C.; Wissler, M.; Klanke, C.; Weissenbach, J.; Alexander, I.; Fischer, A.; von Kalle, C. and Cavazzana-Calvo, M. (2007): Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy, J Clin Invest 117 [8], pp.2225-32. [82] Schwarzwaelder, K.; Howe, S. J.; Schmidt, M.; Brugman, M. H.; Deichmann, A.; Glimm, H.; Schmidt, S.; Prinz, C.; Wissler, M.; King, D. J.; Zhang, F.; Parsley, K. L.; Gilmour, K. C.; Sinclair, J.; Bayford, J.; Peraj, R.; Pike-Overzet, K.; Staal, F. J.; de Ridder, D.; Kinnon, C.; Abel, U.; Wagemaker, G.; Gaspar, H. B.; Thrasher, A. J. and von Kalle, C. (2007): Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo, J Clin Invest 117 [8], pp.2241-9. [83] Wu, X.; Li, Y.; Crise, B. and Burgess, S. M. (2003): Transcription start regions in the human genome are favored targets for MLV integration, Science 300 [5626], pp.1749-51. [84] Laufs, S.; Gentner, B.; Nagy, K. Z.; Jauch, A.; Benner, A.; Naundorf, S.; Kuehlcke, K.; Schiedlmeier, B.; Ho, A. D.; Zeller, W. J. and Fruehauf, S. (2003): Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells, Blood 101 [6], pp.2191-8. [85] Kustikova, O.; Fehse, B.; Modlich, U.; Yang, M.; Dullmann, J.; Kamino, K.; von Neuhoff, N.; Schlegelberger, B.; Li, Z. and Baum, C. (2005): Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking, Science 308 [5725], pp.1171-4. [86] Giordano, F. A.; Fehse, B.; Hotz-Wagenblatt, A.; Jonnakuty, S.; del Val, C.; Appelt, J. U.; Nagy, K. Z.; Kuehlcke, K.; Naundorf, S.; Zander, A. R.; Zeller, W. J.; Ho, A. D.; Fruehauf, S. and Laufs, S. (2006): Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions, Bone Marrow Transplant 38 [3], pp.229-35. [87] Recchia, A.; Bonini, C.; Magnani, Z.; Urbinati, F.; Sartori, D.; Muraro, S.; Tagliafico, E.; Bondanza, A.; Stanghellini, M. T.; Bernardi, M.; Pescarollo, A.; Ciceri, F.; Bordignon, C. and Mavilio, F. (2006): Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells, Proc Natl Acad Sci U S A 103 [5], pp.1457-62. [88] Thornhill, S. I.; Schambach, A.; Howe, S. J.; Ulaganathan, M.; Grassman, E.; Williams, D.; Schiedlmeier, B.; Sebire, N. J.; Gaspar, H. B.; Kinnon, C.; Baum, C. and Thrasher, A. J. (2008): Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency, Mol Ther 16 [3], pp.590-8. [89] Yanez-Munoz, R. J.; Balaggan, K. S.; MacNeil, A.; Howe, S. J.; Schmidt, M.; Smith, A. J.; Buch, P.; MacLaren, R. E.; Anderson, P. N.; Barker, S. E.; Duran, Y.; Bartholomae, C.; von Kalle, C.; Heckenlively, J. R.; Kinnon, C.; Ali, R. R. and Thrasher, A. J. (2006): Effective gene therapy with nonintegrating lentiviral vectors, Nat Med 12 [3], pp.348-53. [90] Ginsburg, D. S. and Calos, M. P. (2005): Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes, Adv Genet 54, pp.179-87. [91] Vassaux, G. and Martin-Duque, P. (2004): Use of suicide genes for cancer gene therapy: study of the different approaches, Expert Opin Biol Ther 4 [4], pp.519-30. [92] Niculescu-Duvaz, I. and Springer, C. J. (2005): Introduction to the background, principles, and state of the art in suicide gene therapy, Mol Biotechnol 30 [1], pp.71-88. [93] Freeman, S. M.; Whartenby, K. A.; Freeman, J. L.; Abboud, C. N. and Marrogi, A. J. (1996): In situ use of suicide genes for cancer therapy, Semin Oncol 23 [1], pp.31-45. [94] Ciceri, F.; Bonini, C.; Gallo-Stampino, C. and Bordignon, C. (2005): Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation, Cytotherapy 7 [2], pp.144-9. [95] Bonini, C.; Bondanza, A.; Perna, S. K.; Kaneko, S.; Traversari, C.; Ciceri, F. and Bordignon, C. (2007): The suicide gene therapy challenge: how to improve a successful gene therapy approach, Mol Ther 15 [7], pp.1248-52. [96] Tiberghien, P. (2001): Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation, J Intern Med 249 [4], pp.369-77. [97] Tiberghien, P.; Ferrand, C.; Lioure, B.; Milpied, N.; Angonin, R.; Deconinck, E.; Certoux, J. M.; Robinet, E.; Saas, P.; Petracca, B.; Juttner, C.; Reynolds, C. W.; Longo, D. L.; Herve, P. and Cahn, J. Y. (2001): Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft, Blood 97 [1], pp.63-72. [98] Bonini, C.; Ferrari, G.; Verzeletti, S.; Servida, P.; Zappone, E.; Ruggieri, L.; Ponzoni, M.; Rossini, S.; Mavilio, F.; Traversari, C. and Bordignon, C. (1997): HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science 276 [5319], pp.1719-24. [99] Riddell, S. R.; Elliott, M.; Lewinsohn, D. A.; Gilbert, M. J.; Wilson, L.; Manley, S. A.; Lupton, S. D.; Overell, R. W.; Reynolds, T. C.; Corey, L. and Greenberg, P. D. (1996): T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients, Nat Med 2 [2], pp.216-23. [100] Ciceri, F.; Bonini, C.; Marktel, S.; Zappone, E.; Servida, P.; Bernardi, M.; Pescarollo, A.; Bondanza, A.; Peccatori, J.; Rossini, S.; Magnani, Z.; Salomoni, M.; Benati, C.; Ponzoni, M.; Callegaro, L.; Corradini, P.; Bregni, M.; Traversari, C. and Bordignon, C. (2007): Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation, Blood 109 [11], pp.4698-707. [101] Berger, C.; Flowers, M. E.; Warren, E. H. and Riddell, S. R. (2006): Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation, Blood 107 [6], pp.2294-302. [102] Traversari, C.; Marktel, S.; Magnani, Z.; Mangia, P.; Russo, V.; Ciceri, F.; Bonini, C. and Bordignon, C. (2007): The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies, Blood 109 [11], pp.4708-15. [103] Frank, O.; Rudolph, C.; Heberlein, C.; von Neuhoff, N.; Schrock, E.; Schambach, A.; Schlegelberger, B.; Fehse, B.; Ostertag, W.; Stocking, C. and Baum, C. (2004): Tumor cells escape suicide gene therapy by genetic and epigenetic instability, Blood 104 [12], pp.3543-9. [104] Deschamps, M.; Mercier-Lethondal, P.; Certoux, J. M.; Henry, C.; Lioure, B.; Pagneux, C.; Cahn, J. Y.; Deconinck, E.; Robinet, E.; Tiberghien, P. and Ferrand, C. (2007): Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft, Blood 110 [12], pp.3842-52. [105] Junker, K.; Koehl, U.; Zimmerman, S.; Stein, S.; Schwabe, D.; Klingebiel, T. and Grez, M. (2003): Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes, Gene Ther 10 [14], pp.1189-97. [106] Thomis, D. C.; Marktel, S.; Bonini, C.; Traversari, C.; Gilman, M.; Bordignon, C. and Clackson, T. (2001): A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease, Blood 97 [5], pp.1249-57. [107] Straathof, K. C.; Pule, M. A.; Yotnda, P.; Dotti, G.; Vanin, E. F.; Brenner, M. K.; Heslop, H. E.; Spencer, D. M. and Rooney, C. M. (2005): An inducible caspase 9 safety switch for T-cell therapy, Blood 105 [11], pp.4247-54. [108] Tey, S. K.; Dotti, G.; Rooney, C. M.; Heslop, H. E. and Brenner, M. K. (2007): Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation, Biol Blood Marrow Transplant 13 [8], pp.913-24. [109] Berger, C.; Blau, C. A.; Huang, M. L.; Iuliucci, J. D.; Dalgarno, D. C.; Gaschet, J.; Heimfeld, S.; Clackson, T. and Riddell, S. R. (2004): Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model, Blood 103 [4], pp.1261-9. [110] Quintarelli, C.; Vera, J. F.; Savoldo, B.; Giordano Attianese, G. M.; Pule, M.; Foster, A. E.; Heslop, H. E.; Rooney, C. M.; Brenner, M. K. and Dotti, G. (2007): Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes, Blood 110 [8], pp.2793-802. [111] Introna, M.; Barbui, A. M.; Bambacioni, F.; Casati, C.; Gaipa, G.; Borleri, G.; Bernasconi, S.; Barbui, T.; Golay, J.; Biondi, A. and Rambaldi, A. (2000): Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies, Hum Gene Ther 11 [4], pp.611-20. [112] van Meerten, T.; Claessen, M. J.; Hagenbeek, A. and Ebeling, S. B. (2006): The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells, Gene Ther 13 [9], pp.789-97. [113] Serafini, M.; Bonamino, M.; Golay, J. and Introna, M. (2004): Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis, Haematologica 89 [1], pp.86-95. [114] Smith, M. R. (2003): Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance, Oncogene 22 [47], pp.7359-68. [115] van Meerten, T.; van Rijn, R. S.; Hol, S.; Hagenbeek, A. and Ebeling, S. B. (2006): Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity, Clin Cancer Res 12 [13], pp.4027-35. [116] Algino, K. M.; Thomason, R. W.; King, D. E.; Montiel, M. M. and Craig, F. E. (1996): CD20 (pan-B cell antigen) expression on bone marrow-derived T cells, Am J Clin Pathol 106 [1], pp.78-81. [117] Serafini, M.; Manganini, M.; Borleri, G.; Bonamino, M.; Imberti, L.; Biondi, A.; Golay, J.; Rambaldi, A. and Introna, M. (2004): Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease, Hum Gene Ther 15 [1], pp.63-76. [118] Yuan, R. R.; Wong, P.; McDevitt, M. R.; Doubrovina, E.; Leiner, I.; Bornmann, W.; O'Reilly, R.; Pamer, E. G. and Scheinberg, D. A. (2004): Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers, Blood 104 [8], pp.2397-402. [119] Hess, P. R.; Barnes, C.; Woolard, M. D.; Johnson, M. D.; Cullen, J. M.; Collins, E. J. and Frelinger, J. A. (2007): Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin, Blood 109 [8], pp.3300-7. [120] Casares, S.; Stan, A. C.; Bona, C. A. and Brumeanu, T. D. (2001): Antigen-specific downregulation of T cells by doxorubicin delivered through a recombinant MHC II--peptide chimera, Nat Biotechnol 19 [2], pp.142-7. [121] O'Herrin, S. M.; Slansky, J. E.; Tang, Q.; Markiewicz, M. A.; Gajewski, T. F.; Pardoll, D. M.; Schneck, J. P. and Bluestone, J. A. (2001): Antigen-specific blockade of T cells in vivo using dimeric MHC peptide, J Immunol 167 [5], pp.2555-60. [122] Casares, S.; Bona, C. A. and Brumeanu, T. D. (2001): Modulation of CD4 T cell function by soluble MHC II-peptide chimeras, Int Rev Immunol 20 [5], pp.547-73. [123] Maile, R.; Wang, B.; Schooler, W.; Meyer, A.; Collins, E. J. and Frelinger, J. A. (2001): Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers, J Immunol 167 [7], pp.3708-14. [124] Casares, S.; Zong, C. S.; Radu, D. L.; Miller, A.; Bona, C. A. and Brumeanu, T. D. (1999): Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation, J Exp Med 190 [4], pp.543-53. [125] Uckert, W.; Kammertons, T.; Haack, K.; Qin, Z.; Gebert, J.; Schendel, D. J. and Blankenstein, T. (1998): Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo, Hum Gene Ther 9 [6], pp.855-65. [126] O'Brien, T. A.; Tuong, D. T.; Basso, L. M.; McIvor, R. S. and Orchard, P. J. (2006): Coexpression of the uracil phosphoribosyltransferase gene with a chimeric human nerve growth factor receptor/cytosine deaminase fusion gene, using a single retroviral vector, augments cytotoxicity of transduced human T cells exposed to 5-fluorocytosine, Hum Gene Ther 17 [5], pp.518-30. [127] Woods, N. B.; Muessig, A.; Schmidt, M.; Flygare, J.; Olsson, K.; Salmon, P.; Trono, D.; von Kalle, C. and Karlsson, S. (2003): Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis, Blood 101 [4], pp.1284-9. [128] Sussman, J. J.; Parihar, R.; Winstead, K. and Finkelman, F. D. (2004): Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion, Cancer Res 64 [24], pp.9124-30. [129] Stitz, J.; Buchholz, C. J.; Engelstadter, M.; Uckert, W.; Bloemer, U.; Schmitt, I. and Cichutek, K. (2000): Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1, Virology 273 [1], pp.16-20. [130] Kurts, C.; Heath, W. R.; Carbone, F. R.; Allison, J.; Miller, J. F. and Kosaka, H. (1996): Constitutive class I-restricted exogenous presentation of self antigens in vivo, J Exp Med 184 [3], pp.923-30. [131] Morita, S.; Kojima, T. and Kitamura, T. (2000): Plat-E: an efficient and stable system for transient packaging of retroviruses, Gene Ther 7 [12], pp.1063-6. [132] Letourneur, F. and Malissen, B. (1989): Derivation of a T cell hybridoma variant deprived of functional T cell receptor alpha and beta chain transcripts reveals a nonfunctional alpha-mRNA of BW5147 origin, Eur J Immunol 19 [12], pp.2269-74. [133] Karttunen, J.; Sanderson, S. and Shastri, N. (1992): Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens, Proc Natl Acad Sci U S A 89 [13], pp.6020-4. [134] Heemskerk, M. H.; Hoogeboom, M.; de Paus, R. A.; Kester, M. G.; van der Hoorn, M. A.; Goulmy, E.; Willemze, R. and Falkenburg, J. H. (2003): Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region, Blood 102 [10], pp.3530-40. [135] Bendtsen, J. D.; Nielsen, H.; von Heijne, G. and Brunak, S. (2004): Improved prediction of signal peptides: SignalP 3.0, J Mol Biol 340 [4], pp.783-95. [136] Reuss, S.; Biese, P.; Cosset, F. L.; Takeuchi, Y. and Uckert, W. (2007): Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles, Gene Ther 14 [7], pp.595-603. [137] McNicol, A. M.; Bendle, G.; Holler, A.; Matjeka, T.; Dalton, E.; Rettig, L.; Zamoyska, R.; Uckert, W.; Xue, S. A. and Stauss, H. J. (2007): CD8alpha/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR, Eur J Immunol 37 [6], pp.1634-41. [138] Berger, C.; Jensen, M. C.; Lansdorp, P. M.; Gough, M.; Elliott, C. and Riddell, S. R. (2008): Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates, J Clin Invest 118 [1], pp.294-305. [139] Kurts, C.; Miller, J. F.; Subramaniam, R. M.; Carbone, F. R. and Heath, W. R. (1998): Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction, J Exp Med 188 [2], pp.409-14. [140] de Witte, M. A.; Coccoris, M.; Wolkers, M. C.; van den Boom, M. D.; Mesman, E. M.; Song, J. Y.; van der Valk, M.; Haanen, J. B. and Schumacher, T. N. (2006): Targeting self-antigens through allogeneic TCR gene transfer, Blood 108 [3], pp.870-7. [141] Jorritsma, A.; Gomez-Eerland, R.; Dokter, M.; van de Kasteele, W.; Zoet, Y. M.; Doxiadis, II; Rufer, N.; Romero, P.; Morgan, R. A.; Schumacher, T. N. and Haanen, J. B. (2007): Selecting highly affine and well-expressed TCRs for gene therapy of melanoma, Blood 110 [10], pp.3564-72. [142] Daudt, L.; Maccario, R.; Locatelli, F.; Turin, I.; Silla, L.; Montini, E.; Percivalle, E.; Giugliani, R.; Avanzini, M. A.; Moretta, A. and Montagna, D. (2008): Interleukin-15 Favors the Expansion of Central Memory CD8+ T Cells in Ex Vivo Generated, Antileukemia Human Cytotoxic T Lymphocyte Lines, J Immunother. [143] Kishore, U. and Reid, K. B. (2000): C1q: structure, function, and receptors, Immunopharmacology 49 [1-2], pp.159-70. [144] Fehse, B.; Kustikova, O. S.; Li, Z.; Wahlers, A.; Bohn, W.; Beyer, W. R.; Chalmers, D.; Tiberghien, P.; Kuhlcke, K.; Zander, A. R. and Baum, C. (2002): A novel 'sort-suicide' fusion gene vector for T cell manipulation, Gene Ther 9 [23], pp.1633-8. [145] Antony, P. A.; Piccirillo, C. A.; Akpinarli, A.; Finkelstein, S. E.; Speiss, P. J.; Surman, D. R.; Palmer, D. C.; Chan, C. C.; Klebanoff, C. A.; Overwijk, W. W.; Rosenberg, S. A. and Restifo, N. P. (2005): CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells, J Immunol 174 [5], pp.2591-601. [146] Dummer, W.; Niethammer, A. G.; Baccala, R.; Lawson, B. R.; Wagner, N.; Reisfeld, R. A. and Theofilopoulos, A. N. (2002): T cell homeostatic proliferation elicits effective antitumor autoimmunity, J Clin Invest 110 [2], pp.185-92. [147] Gattinoni, L.; Klebanoff, C. A.; Palmer, D. C.; Wrzesinski, C.; Kerstann, K.; Yu, Z.; Finkelstein, S. E.; Theoret, M. R.; Rosenberg, S. A. and Restifo, N. P. (2005): Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells, J Clin Invest 115 [6], pp.1616-26. [148] Beck, C.; Cayeux, S.; Lupton, S. D.; Dorken, B. and Blankenstein, T. (1995): The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells, Hum Gene Ther 6 [12], pp.1525-30. [149] Hilpert, K.; Hansen, G.; Wessner, H.; Kuttner, G.; Welfle, K.; Seifert, M. and Hohne, W. (2001): Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose, Protein Eng 14 [10], pp.803-6. [150] Salfeld, J. G. (2007): Isotype selection in antibody engineering, Nat Biotechnol 25 [12], pp.1369-72. [151] Strome, S. E.; Sausville, E. A. and Mann, D. (2007): A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects, Oncologist 12 [9], pp.1084-95. [152] Jefferis, R. (2007): Antibody therapeutics: isotype and glycoform selection, Expert Opin Biol Ther 7 [9], pp.1401-13. [153] Mirick, G. R.; Bradt, B. M.; Denardo, S. J. and Denardo, G. L. (2004): A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words, Q J Nucl Med Mol Imaging 48 [4], pp.251-7. [154] Lonberg, N. (2008): Human monoclonal antibodies from transgenic mice, Handb Exp Pharmacol [181], pp.69-97. [155] Reichert, J. M.; Rosensweig, C. J.; Faden, L. B. and Dewitz, M. C. (2005): Monoclonal antibody successes in the clinic, Nat Biotechnol 23 [9], pp.1073-8. [156] Samuels, J.; Ng, Y. S.; Coupillaud, C.; Paget, D. and Meffre, E. (2005): Human B cell tolerance and its failure in rheumatoid arthritis, Ann N Y Acad Sci 1062, pp.116-26. [157] Goodnow, C. C.; Crosbie, J.; Jorgensen, H.; Brink, R. A. and Basten, A. (1989): Induction of self-tolerance in mature peripheral B lymphocytes, Nature 342 [6248], pp.385-91. [158] Maine, G. N. and Mulé, J. J. (2002): Making room for T cells, J. Clin. Invest. 110 [2], pp.157-159. [159] Liu, H.; Rhodes, M.; Wiest, D. L. and Vignali, D. A. (2000): On the dynamics of TCR:CD3 complex cell surface expression and downmodulation, Immunity 13 [5], pp.665-75. [160] Goldrath, A. W.; Luckey, C. J.; Park, R.; Benoist, C. and Mathis, D. (2004): The molecular program induced in T cells undergoing homeostatic proliferation, Proc Natl Acad Sci U S A 101 [48], pp.16885-90. [161] Kume, A.; Koremoto, M.; Mizukami, H.; Okada, T.; Hanazono, Y.; Sugamura, K. and Ozawa, K. (2002): Selective growth advantage of wild-type lymphocytes in X-linked SCID recipients, Bone Marrow Transplant 30 [2], pp.113-8. [162] Hertenstein, B.; Wagner, B.; Bunjes, D.; Duncker, C.; Raghavachar, A.; Arnold, R.; Heimpel, H. and Schrezenmeier, H. (1995): Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma, Blood 86 [4], pp.1487-92. [163] Jurianz, K.; Ziegler, S.; Garcia-Schuler, H.; Kraus, S.; Bohana-Kashtan, O.; Fishelson, Z. and Kirschfink, M. (1999): Complement resistance of tumor cells: basal and induced mechanisms, Mol Immunol 36 [13-14], pp.929-39. [164] Gorter, A. and Meri, S. (1999): Immune evasion of tumor cells using membrane-bound complement regulatory proteins, Immunol Today 20 [12], pp.576-82. [165] Okroj, M.; Hsu, Y. F.; Ajona, D.; Pio, R. and Blom, A. M. (2008): Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors, Mol Immunol 45 [1], pp.169-79. [166] Van Wauwe, J. P.; De Mey, J. R. and Goossens, J. G. (1980): OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties, J Immunol 124 [6], pp.2708-13. [167] Granger, S.; Janossy, G.; Francis, G.; Blacklock, H.; Poulter, L. W. and Hoffbrand, A. V. (1982): Elimination of T-lymphocytes from human bone marrow with monoclonal T-antibodies and cytolytic complement, Br J Haematol 50 [2], pp.367-74. [168] Hirsch, R.; Eckhaus, M.; Auchincloss, H., Jr.; Sachs, D. H. and Bluestone, J. A. (1988): Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses, J Immunol 140 [11], pp.3766-72. [169] Hirsch, R.; Gress, R. E.; Pluznik, D. H.; Eckhaus, M. and Bluestone, J. A. (1989): Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells, J Immunol 142 [3], pp.737-43. [170] Ellenhorn, J. D.; Hirsch, R.; Hartley, J. P. and Bluestone, J. A. (1989): Dose-dependent activation of murine T cells following in vivo administration of anti-murine CD3, Transplant Proc 21 [1 Pt 1], pp.1013-4. [171] Schiweck, W.; Buxbaum, B.; Schatzlein, C.; Neiss, H. G. and Skerra, A. (1997): Sequence analysis and bacterial production of the anti-c-myc antibody 9E10: the V(H) domain has an extended CDR-H3 and exhibits unusual solubility, FEBS Lett 414 [1], pp.33-8.